Antipsychotic Discontinuation in Alzheimer's Disease
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
Schizophrenia, Alzheimer Disease, ...DrugFrom 50 Years to 95 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether risperidone may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive risperidone, attend study visits with the research team. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 7 sites
Tuscaloosa VA Medical Center, Department of Psychiatry
Tuscaloosa, Alabama
Site status: Not listed — confirm with the team
WLA VA Medical Center/UCLA, Psychiatry
Los Angeles, California
Site status: Not listed — confirm with the team
Research Center for Clinical Studies, Inc.
Norwalk, Connecticut
Site status: Not listed — confirm with the team
University of Iowa College of Medicine
Iowa City, Iowa
Site status: Not listed — confirm with the team
Mount Sinai School of Medicine, Alzheimer's Disease Research Center
New York, New York
Site status: Not listed — confirm with the team
New York State Psychiatric Institute, Columbia University
New York, New York
Site status: Not listed — confirm with the team
Medical University of South Carolina
North Charleston, South Carolina
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving risperidone. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 50 Years to 95 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by New York State Psychiatric Institute, which appears to be a research institute. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
